Order S E
Dept of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD 21205.
Int J Radiat Oncol Biol Phys. 1988;14 Suppl 1:S77-81.
The radiolabeled antibody studies of RTOG have introduced a new class of agents in cancer therapy and demonstrated the transport ability of a new technology using agents that cause no acute symptoms, that can be administered in some instances on an out patient basis and that remit active disease in a variety of sites. The potential for new results has been amplified by the recent accomplishment of the chelation of 111-Indium and 90-Yttrium as both dosimetric and therapeutic isotopes linked to antibodies for systemic therapy (Table 2). These developments by a commercial corporation to produce large quantities of radiolabeled antibody agents allow a greater freedom of investigation with these new agents. Once appropriate identification of antibody and dosimetric evaluations are carried out, their additive or singular effects can be studied in a number of malignancies. The need for development of centers to carry out such studies and group-wide dissemination are potential limiting factors. A variety of new combinations of antibody and isotope, increasing specific activity in a number of ways, needs to be investigated in laboratories and in clinics by integrated teams. Radiolabeled antibody therapy has at present the potential to contribute to conventional therapies with both radiation and chemotherapy in a variety of malignancies while not increasing the need for hospitalization and yet minimizing patient discomfort.
放射肿瘤学组（RTOG）的放射性标记抗体研究在癌症治疗中引入了一类新型药物，并展示了一种新技术的转运能力，该技术使用的药物不会引起急性症状，在某些情况下可在门诊给药，且能缓解多个部位的活动性疾病。111-铟和90-钇作为与用于全身治疗的抗体相连的剂量测定和治疗性同位素，近期已实现螯合，这进一步扩大了取得新成果的可能性（表2）。一家商业公司开发出大量生产放射性标记抗体药物的技术，使得对这些新型药物的研究更加自由。一旦对抗体进行了适当鉴定并完成剂量测定评估，就可以在多种恶性肿瘤中研究它们的相加或单一效应。开展此类研究的中心的发展需求以及全组范围内的推广是潜在的限制因素。抗体与同位素的各种新组合，以多种方式提高比活度，需要由综合团队在实验室和临床中进行研究。目前，放射性标记抗体疗法有潜力在多种恶性肿瘤中为传统的放疗和化疗做出贡献。同时，该疗法不会增加住院需求，还能将患者不适降至最低。
